STAT+ highlighted how the search for durable KRAS-mutant therapies has accelerated since early KRAS drugs fell short on response durability. The report centers on Revolution Medicines’ daraxonrasib as a leading program in the clinic, but it also surveys a widening field of competitors testing KRAS inhibitors in trials. It frames the shift as a move from earlier “can we drug it” efforts toward strategies designed for broader patient coverage and improved clinical staying power. The patient story underscores how trial access can materially change outcomes in metastatic pancreatic cancer, a disease where historical survival remains poor. For investors and pipeline planners, the piece signals that KRAS therapeutics is becoming a crowded late-development arena, making trial design, biomarker strategy, and durability the key differentiators.